Zydus Lifesciences Ltd.

BSE: 532321 | NSE: ZYDUSLIFE

Mid Cap | Pharmaceuticals & Drugs

942.55

3.35 (0.36%)

< Home < Back

Zydus Lifesciences Ltd. News

>>

Cadila Healthcare plans to launch molecule for diabetes dyslipidemia: Report

>>

Zydus Cadila gains on receives tentative approval from USFDA for Doxepin HcI tablets

>>

Zydus Cadila receives tentative approval from USFDA for Doxepin HcI tablets

>>

Zydus Cadila gets final USFDA approval for Ranitidine HcI injection

>>

Cadila Healthcare advances on receiving USFDA nod for marketing anti-diabetic drug

>>

Zydus Cadila receives final approval for Pioglitazone HC1 tablets

>>

Cadila Healthcare reports 75% fall in Q3 net profit

>>

Cadila Healthcare to consider unaudited financial results

>>

Cadila Healthcare submits disclosure

>>

Cadila Healthcare reports 7% fall in consolidated Q2 net profit

<< < 164 165 166 ...168 > >>